Loading market dashboard
AC Immune S.A.
ACIUHealthcareNASDAQCH
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients with amyotrophic lateral sclerosis (ALS) Previously reported data also showed detection of TDP-43 in patients with genetically defined frontotemporal dementia (FTD) Underlines potential for precision medicine enabling early diagnosis and intervention in multiple neurodegenerative diseases Lausanne, Switzerland, May 22, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography (PET) tracer ACI-19626 showing increased uptake in the brains of patients with amyotrophic lateral sclerosis (ALS). The results presented at the 2026 TDP43 Summit in Madison, Wisconsin, demonstrate that PET scans with ACI-19626 showed tracer uptake significantly higher in key regions of the brain in patients with ALS compared to healthy controls.
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appointed interim CEO Dr Pfeifer to serve as an Advisor and Honorary Chair of the Board of Directors, and Co-Chair of the Scientific Advisory Board Company well-positioned to drive short- and long-term value creation via its wholly-owned pipeline and strategic partnerships Robust balance sheet following recently achieved milestones, with multiple further near-term value-inflection milestones Lausanne, Switzerland, 12 May 2026 -- AC Immune SA (Nasdaq: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that Dr Andrea Pfeifer has decided to retire from her role as Chief Executive Officer (CEO) of AC Immune at the upcoming Annual General Meeting (AGM) to spend more time with her family. AC Immune's Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.
AC Immune (ACIU) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.21 per share a year ago.
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 2026 Initiated final cohort, AD4, in ABATE Phase 1b/2 trial of ACI-24 to treat Alzheimer's Disease triggers milestone payment, as announced separately today Amended Morphomer® Tau collaboration with Lilly reflects growing excitement for targeting intracellular Tau and significant progress with our Morphomer® small molecules Approaching multiple milestones including 12-month interim results of the AD3 cohort in ABATE in Q2 2026 and full data from Part 1 of ACI-7104 VacSYn Phase 2 trial expected in H2 2026 Cash resources of CHF 74.8 million as of March 31, 2026, provide funding into Q4 2027 Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today provided financial and corporate updates for the quarter ended March 31, 2026. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our anti-Abeta active immunotherapy and Tau aggregation inhibitor small molecules, respectively.
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone payment Allows evaluation of potential for precision prevention of neurodegenerative diseases Data from ABATE Cohorts AD1, AD2 and AD3 after 12 months treatment expected Q2 2026 Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it dosed the first patients in Cohort AD4 in the ongoing Phase 1b/2 ABATE trial. As a result, AC Immune will receive a $12 million milestone payment from Takeda under the partners' exclusive, worldwide option and license agreement for AC Immune's active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24 for the treatment of Alzheimer's disease (AD).
AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphomer candidates and boosting long-term Alzheimer's strategy.
Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this year.
This will help fund the biotech's development of a unique treatment for neurodegenerative diseases like Alzheimer's. The company could earn more than $2.1 billion if this work is successful.
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significant progress made with our Morphomer small molecules Investigational New Drug (IND)-enabling studies to commence in H1 2026 Lausanne, Switzerland, April 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced an agreement with Eli Lilly and Company (Lilly) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. The amendment continues the research and collaboration to cover development of new lead Tau Morphomer® candidates and potential back-up compounds.
AC Immune (ACIU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how AC Immune (ACIU) and Anavex Life Sciences (AVXL) have performed compared to their sector so far this year.
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's disease NLRP3 inhibitor ACI-19764 Phase 1 trial initiated with first participants dosed Approaching multiple value-inflection points, including interim results of the AD3 cohort in the Phase 2 ABATE trial of ACI-24 in Alzheimer's disease in H1 2026, and full 24-month data from Part 1 of the Phase 2 VacSYn trial of ACI-7104 in Q3 2026 Cash resources of CHF 91.4 million as of December 31, 2025, provide funding to the end of Q3 2027 before any potential milestone payments Lausanne, Switzerland, March 13, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended December 31, 2025, and provided a corporate update. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We made significant progress towards delivering precision prevention of neurodegenerative diseases in 2025, exemplified by the exceptional interim data from the VacSYn trial of ACI-7104, our wholly-owned active immunotherapy targeting α-synuclein.
